NCBI Logo
GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
          Go
Series GSE178157 Query DataSets for GSE178157
Status Public on Oct 01, 2023
Title Niclosamide as a chemical probe for analyzing SARS-CoV-2 modulation of host cell lipid metabolism
Organism Chlorocebus sabaeus
Experiment type Expression profiling by high throughput sequencing
Summary Purpose: The global effort to combat COVID-19 rapidly produced a shortlist of approved drugs with anti-viral activities for clinical repurposing. However, the jump to clinical testing was lethal in some cases since a full understanding of the mechanism of antiviral activity as opposed to inherent toxicity for these drugs was lacking. We used parallel lipidomic and transcriptomic analyses to investigate the effect of Niclosamide (NIC), a poorly soluble anti-helminth drug identified for repurposed treatment of COVID-19, on SARS-CoV-2 infected Vero E6 cells.
Methods: A time of addition study was performed on VeroE6 cells to gain mRNA profiles of 16 and 48h SARS-CoV-2 and/or niclosamide infected cells in triplicate, using an Illumina NovaSeq6000 platfrom. Sequence reads that passed quality filters were analyzed by featurecounts and DESeq2.
Results: Herein, we identified and characterized autophagic or lipophagic pathways (and wider linked cellular networks) that are targeted by NIC in the presence and absence of a SARS-CoV-2 infection. We used the lipid and gene expression signatures induced by this anti-parasitic compound to detect pathways that are predicted to either lead to direct antiviral effects or to cellular dysregulation and cell death.
Conclusions: NIC treatment reduced the abundance of phosphatidylethanolamines (PE), a known activator of autophagy, only after establishment of SARS-CoV-2 infection. Countering SARS-CoV-2 subversion of lipid metabolism by NIC through the activation of PE may lead to a focused screen for approved, more druggable compounds that can suppress viral replication in COVID-19 patients.
 
Overall design Vero E6 cell mRNA profiles at 0h, 16h or 48h treated and/or infected with NIC or SARS-CoV-2
 
Contributor(s) Coatsworth H, Ayers JB
Citation(s) 37901834
Submission date Jun 14, 2021
Last update date Nov 13, 2023
Contact name Rhoel Dinglasan
E-mail(s) rdinglasan@epi.ufl.edu
Organization name University of Florida
Street address 2055 Mowry Rd
City Gainesville
State/province Florida
ZIP/Postal code 32601
Country USA
 
Platforms (1)
GPL28895 Illumina NovaSeq 6000 (Chlorocebus sabaeus)
Samples (26)
GSM5381081 Vero E6 untreated samples at 0 hours rep1
GSM5381082 Vero E6 untreated samples at 0 hours rep2
GSM5381083 Vero E6 untreated samples at 0 hours rep3
Relations
BioProject PRJNA737484
SRA SRP324007

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE178157_RAW.tar 3.6 Mb (http)(custom) TAR (of TAB)
SRA Run SelectorHelp
Raw data are available in SRA
Processed data provided as supplementary file
| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap